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Glycosylation processes are under high natural se-
lection pressure, presumably because these can
modulate resistance to infection. Here, we asked
whether inactivation of the UDP-galactose:b-galac-
toside-a1-3-galactosyltransferase (a1,3GT) gene,
which ablated the expression of the Gala1-3Galb1-
4GlcNAc-R (a-gal) glycanandallowed for theproduc-
tion of anti-a-gal antibodies (Abs) in humans, confers
protection against Plasmodium spp. infection, the
causative agent of malaria and a major driving force
in human evolution. We demonstrate that both Plas-
modium spp. and the human gut pathobiont E. coli
O86:B7 express a-gal and that anti-a-gal Abs are
associated with protection against malaria transmis-
sion in humans as well as in a1,3GT-deficient mice,
which produce protective anti-a-gal Abs when
colonized by E. coli O86:B7. Anti-a-gal Abs target
Plasmodium sporozoites for complement-mediated
cytotoxicity in the skin, immediately after inoculation
by Anophelesmosquitoes. Vaccination against a-gal
confers sterile protection against malaria in mice,
suggesting that a similar approach may reduce
malaria transmission in humans.INTRODUCTION
Humans have relatively high levels of circulating antibodies
(Abs) recognizing xeno-glycans expressed by pathogens (Oye-
laran et al., 2009). As for other antigens, xeno-glycans cannot
be targeted by the immune system when also expressed asself-glycans. This limitation can be bypassed by natural selec-
tion of mutations that inactivate the expression of self-glycans
(Bishop and Gagneux, 2007). Presumably, natural selection of
such loss-of-function mutations tailored the human anti-glycan
immune repertoire through evolution (Bishop and Gagneux,
2007). This notion is supported by the inactivation of the cyti-
dine monophosphate-N-acetylneuraminic acid hydroxylase-
like (CMAH) gene in humans, which suppressed the expression
of N-glycolylneuraminic acid (Neu5Gc) (Hayakawa et al., 2001)
and allowed for immune reactivity against Neu5Gc (Tangvora-
nuntakul et al., 2003). In a similar manner, inactivation of the
a1,3GT gene, which suppressed the expression of the Gala1-
3Galb1-4GlcNAc-R (a-gal) carbohydrate in ancestral anthropoid
primates that gave rise to humans (Galili and Swanson, 1991),
also allowed for immune reactivity against a-gal (Galili et al.,
1984). While it has been argued that this evolutionary process
is driven to a large extent by the acquisition of immune-resis-
tance against pathogens expressing such glycans (Bishop and
Gagneux, 2007; Cywes-Bentley et al., 2013), this was never
tested experimentally.
Humans do not express a-gal and up to 1%–5% of the reper-
toire of circulating immunoglobulin M (IgM) and immunoglobulin
G (IgG) in healthy adults is directed against this glycan (Macher
and Galili, 2008). Production of a-gal-specific Abs is thought to
be driven by exposure to bacterial components of the microbiota
expressing a-gal (Macher and Galili, 2008), including specific
members of the Klebsiella spp., Serratia spp., and Escherichia
coli spp. (Galili et al., 1988). Expression of a-gal by these Entero-
bacteriaceae is associatedwith the bacterial capsule and cell wall
glycoproteins, as well as with lipopolysaccharide (LPS) (Galili
et al., 1988). Gut colonization by the human pathobiont E. coli
O86:B7 (Pal et al., 1969) recapitulates the etiology of anti-a-gal
Ab production in mice (Posekany et al., 2002) and in primates
(Man˜ez et al., 2001), as well as the production of Abs directed
against the a-gal-related anti-B blood group glycan in chickensCell 159, 1277–1289, December 4, 2014 ª2014 The Authors 1277
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Figure 1. Detection of a-Gal in Plasmodium
Sporozoites
(A) Composite images of GFP/actin (green), a-gal
(red; white arrows), and DNA (blue) in Plasmodium
sporozoites.
(B) Same staining as (A), after removal of a-gal by
a-galactosidase. Images are representative of 2–3
independent experiments. Scale bar, 5 mm.
(C) Detection of a-gal in PbAHsp70-GFP sporozoites
by flow cytometry, representative of three inde-
pendent experiments.
(D) Detection of a-gal in proteins extracted from
salivary glands of noninfected (NI), P. falciparum
3D7 (Pf), PbAHsp70-GFP (Pb), or P. yoelii 17XNL (Py)-
infected A. mosquitoes. Histone H3 (Hist3) and
GFP were detected as loading controls. When
indicated, a-gal was digested using a-galactosi-
dase (E).
(E and F) Detection of a-gal (E) and CSP (F)
in PbAHsp70-GFP sporozoites treated or not with
phospholipase C (+PLC). Control is not stained.
Data representative of 2–4 independent experi-
ments.
See also Figure S1.(Springer et al., 1959) and humans (Springer and Horton, 1969).
This argues that gut colonization by E. coliO86:B7may be partic-
ularly relevant in triggering the production of a-gal-specific Abs,
presumably contributing to the high titers of these circulating
Abs in healthy adult humans (Galili et al., 1988). Moreover, anti-
a-gal Absmay also be produced in response to infection by path-
ogens expressinga-gal, such illustrated for gram-negative bacte-
ria fromSalmonella spp. or for protozoan parasites from Trypano-
soma spp. (Avila et al., 1989).
Anti-a-gal Abs are cytotoxic toward a-gal-expressing patho-
gens, as demonstrated in vitro for bacteria (Galili et al., 1988),
protozoan parasites (Avila et al., 1989), and viruses enveloped
by xenogeneic a-gal-expressing cell membranes (Takeuchi
et al., 1996). Whether anti-a-gal Abs confer resistance to these
and/or other pathogens in vivo has, to the best of our knowledge,
not been established. Here, we tested this hypothesis specif-
ically for Plasmodium spp. infection, the causative agent of
malaria and a major driving force that shaped the evolution of
anthropoid primates, including humans.1278 Cell 159, 1277–1289, December 4, 2014 ª2014 The AuthorsMalaria is transmitted to humans by the
inoculation of Plasmodium sporozoites
via the bite of female Anopheles (A.)
mosquitoes (Me´nard et al., 2013). While
transmission may be rather efficient,
only a fraction of the inoculated parasites
manage to progress toward the establish-
ment of infection (Rickman et al., 1990;
Sauerwein et al., 2011; Verhage et al.,
2005), hinting at a natural mechanism of
protection that presumably targets the
initial phases of the Plasmodium life cy-
cle. Here, we demonstrate that produc-
tion of anti-a-gal Abs in response to the
gut E. coliO86:B7 pathobiont contributescritically to this natural defense mechanism, reducing malaria
transmission by A. mosquitoes.
RESULTS
Plasmodium spp. Express the a-Gal Glycan
The a-gal glycan was detected on the surface of Plasmodium
sporozoites, as assessed by immunofluorescence for the human
pathogen Plasmodium falciparum 3D7, as well as for the trans-
genic GFP-expressing strains of the rodent pathogens Plasmo-
dium berghei ANKA (PbA) or Plasmodium yoelii 17XNL, using
the lectin Bandeiraea (Griffonia) simplicifolia-I isolectin IB4 (BSI-
B4) (Galili et al., 1985) or an anti-a-gal monoclonal antibody
(M86 mAb) (Galili et al., 1998) (Figure 1A; Figures S1A and
S1B available online). Specificity of a-gal detection was
confirmed by its enzymatic removal using a-galactosidase (Fig-
ures 1B and 1C). Expression of a-gal was associated with
proteins, as assessed by western blot in whole-cell extracts
from P. falciparum 3D7, PbA, or P. yoelii 17XNL sporozoites
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Figure 2. Anti-a-Gal IgM Abs Are Asso-
ciated with Protection against Malaria
Transmission in Individuals from a Malaria
Endemic Region
(A) Anti-a-gal IgM Abs in individuals from a malaria
endemic region in Mali (gray dots) or from the
United States (black dots). Mean (red bars) ± SD.
(B) Levels of anti-a-gal IgM Abs in P. falciparum-
infected (Pf+) versus noninfected (Pf) children >4
years of age are shown as box plots in the same
population as in (A).
(C) Anti-a-gal IgG Abs in individuals from a malaria
endemic region in Mali (gray dots) or from the
United States (black dots). Mean (red bars) ± SD.
(D) Levels of anti-a-gal IgG Abs in P. falciparum-
infected (Pf+) versus noninfected (Pf) children >4
years of age are shown as box plots in the same
population as in (C).(Figure 1D) and confirmed by enzymatic removal of a-gal
(Figure 1D). Residual levels of a-gal were detected in the salivary
glands of noninfected mosquitoes, suggesting that this glycan
may be generated, at least partially, by A. mosquitoes
(Figure 1D).
Expression of a-gal by PbA sporozoites was reduced by 4-
fold when the glycosylphosphatidylinositol (GPI) anchor was
cleaved by phospholipase C (PLC), as assessed by flow cytom-
etry (Figure 1E). In contrast, GPI cleavage failed to reduce the
expression of circumsporozoite protein (CSP), the main protein
expressed at the surface of Plasmodium sporozoites (Figure 1F).
This suggests that a-gal is bound to GPI-anchored surface pro-
teins, including or not CSP, which despite being GPI-anchored
(Moran and Caras, 1994) is resistant to PLC cleavage (Kimmel
et al., 2003) (Figure 1F).
a-Gal-Specific IgM Abs Are Associated with Protection
from P. falciparum Infection in Humans
We investigated whether a correlation exists between the levels
of anti-a-gal Abs in healthy uninfected children and adults before
the malaria season (n = 330 for IgG; n = 229 for IgM) and subse-
quent risk of P. falciparum infection (determined by biweekly
PCR analysis of fingerprick blood samples) and febrile malaria
(determined byweekly physical examination), during the ensuing
6 month malaria season in a cohort study in Mali, where this sea-
son is predictable and intense (Tran et al., 2014). In children <2
years, the average level of anti-a-gal IgM Abs was 33.4 mg/ml
(95% confidence interval [CI]: 18.4–48.3 mg/ml) (Figure 2A),
similar to that reported in children with no history of malaria
exposure (Avila et al., 1992; Doenz et al., 2000; Galili et al.,
1984; Parker et al., 1999). However, anti-a-gal IgM AbsCell 159, 1277–1289, Dincreased with age, reaching an average
of 123.03 mg/ml (95% CI: 79.3–
166.7 mg/ml) in adults— more than twice
the level reported in adults with nomalaria
exposure, i.e., 51.6 mg/ml (95% CI: 14.9–
88.3 mg/ml) (Figure 2A) (Avila et al., 1992;
Doenz et al., 2000; Galili et al., 1984;
Parker et al., 1999). The average level ofanti-a-gal IgM Abs in children >4 years of age who had no
P. falciparum infections detected during the 6-month malaria
season (n = 13) was higher than those who became infected
(n = 141) (Figure 2B). This suggests that there is a positive corre-
lation between the levels of anti-a-gal IgM Abs and incidence of
P. falciparum infection.
The average level of anti-a-gal IgG Abs in children <2 years
was 1.46 mg/ml (95% CI: 0.22–0.69 mg/ml) and increased in
adults to 3.66 mg/ml (95% CI: 3.04–4.28 mg/ml) (Figure 2C). In
contrast to IgM, the levels of circulating a-gal-specific IgG
were similar between malaria-exposed and nonexposed adults,
suggesting that P. falciparum infection fails to drive an IgG
response directed against a-gal (Figure 2D). This also suggests
that there is no correlation between anti-a-gal IgG Abs and inci-
dence of P. falciparum infection. Time-to-event analysis did not
show a correlation between a-gal-specific IgM and IgG levels
before the malaria season and subsequent risk of P. falciparum
infection (p = 0.76 and p = 0.08, respectively) or febrile malaria
(p = 0.35 and p = 0.18, respectively).
Gut Colonization by E. coli O86:B7 Elicits a Protective
a-Gal-Specific IgM Ab Response against Malaria
Transmission
To test whether anti-a-gal IgMAbs are protective against malaria
transmission, we took advantage of ‘‘human-like’’ a1,3Gt-defi-
cient mice. Unlike humans, wild-type mice have a functional
a1,3Gt gene and express a-gal on secreted and cell-surface gly-
coconjugates, suppressing the development of anti-a-gal immu-
nity (Yang et al., 1998). Deletion of a1,3Gt gene eliminates a-gal
(Tearle et al., 1996), allowing for anti-a-gal Ab production in
a1,3Gt/ mice (Chiang et al., 2000; Tearle et al., 1996; Yangecember 4, 2014 ª2014 The Authors 1279
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Figure 3. Gut Colonization by E. coli
Expressing a-Gal Protects against Plasmo-
dium Infection
(A and B) Detection of a-gal in E. coli strains by (A)
flow cytometry and (B) immunofluorescence.
Representative of 2–3 independent experiments.
Composite images in (B), i.e., a-gal (green) and
DNA (blue) at 1003 magnification. Scale bar,
10 mm.
(C and D) a1,3Gt/ mice maintained under SPF
were treated with streptomycin for 7 days. (C) Anti-
a-gal IgM Abs levels were measured in a1,3Gt/
mice not colonized (SPF), colonized with E. coli
K12, or colonized with O86.B7 strains (2–3 exper-
iments; n = 12). (D) Incidence of blood stage of
Plasmodium infection (%) in mice colonized as in
(C) and exposed to PbAEEF1a-GFP-infected
A. stephensi mosquitoes (four experiments; n =
17–34).
(E) Incidence of blood stage of Plasmodium
infection (%) in a1,3Gt/JHT
/, a1,3Gt/Aid/,
and a1,3Gt/mS / mice colonized as in (C) and
exposed to PbAHsp70-GFP-infected A. stephensi
mosquitoes (1–2 experiments; n = 4–10).
(F) Anti-a-gal IgM Abs were measured in GF
a1,3Gt/ mice not colonized (GF), colonized
with E. coli K12, or colonized with O86.B7 strains
(2–3 experiments; n = 12). (G) Incidence of blood
stage of Plasmodium infection (%) in mice colo-
nized as in (F) and exposed to PbAEEF1a-GFP-in-
fected A. stephensimosquitoes (four experiments;
n = 9–13).
Mean (red bars).
See also Figure S2.et al., 1998). However, a1,3Gt/ mice are known to produce
only residual levels of circulating anti-a-gal Abswhenmaintained
under specific pathogen-free (SPF) conditions (Chiang et al.,
2000). Production of anti-a-gal Abs can be enhanced upon
enteric exposure to E. coli O86:B7 (Posekany et al., 2002). We
confirmed that E. coli O86:B7 expresses high levels of a-gal (Yi
et al., 2006), which is not the case for the E. coli K12 strain (Fig-
ures 3A and 3B). Colonization of a1,3Gt/ mice by E. coli
O86:B7 after antibiotic treatment (streptomycin sulfate; 5 g/l in
drinking water for 7 days prior to colonization) increased the
levels of circulating anti-a-gal IgM Abs from 1.4 mg/ml (95% CI:
1.1–1.8 mg/ml) to 162.9 mg/ml (95% CI: 95.89–230.1 mg/ml)
before and after colonization, respectively (Figure 3C). Levels
of anti-a-gal IgM Abs in colonized a1,3Gt/ mice were in the
range of adult individuals from a malaria endemic region (Fig-
ure 2A). In contrast, the levels of circulating anti-a-gal IgGAbs re-
mained at residual levels, i.e., <1 mg/ml (Figure S2A), again in the
range of adult individuals from a malaria endemic region (Fig-1280 Cell 159, 1277–1289, December 4, 2014 ª2014 The Authorsure 2C). Colonization by E. coli K12 did
not induce the production of circulating
anti-a-gal Abs (Figure 3C). Gut coloniza-
tion by E. coli O86.B7 was associated
with protection of a1,3Gt/ mice from
PbA transmission by infected Anopheles
stephensi mosquitoes (Figure 3D). Thiswas not the case when a1,3Gt/ mice were or were not colo-
nized by E. coli K12 (Figure 3D).
To determinewhether the protective effect associatedwith gut
colonization by E. coli O86.B7 is mediated by anti-a-gal Abs, we
performed similar colonization experiments in a1,3Gt/JHT
/
lacking B cells (Gu et al., 1993), a1,3Gt/mS/ mice lacking
circulating IgM (Ehrenstein et al., 1998) or a1,3Gt/Aid/
mice that fail to undergo Ig class switch recombination or so-
matic hypermutation (Muramatsu et al., 2000). Gut colonization
by E. coli O86.B7 failed to protect a1,3Gt/JHT
/ and
a1,3Gt/mS/, but not a1,3Gt/Aid/ mice from PbA-in-
fected mosquitoes, as compared to genetic-matched control
mice colonized or not by E. coli K12 (Figure 3E). This shows
that the protective effect of gut colonization by E. coli O86.B7
acts via a mechanism mediated by anti-a-gal IgM Abs that do
not undergo somatic hypermutation.
Germ-free (GF) a1,3Gt/ mice had low but detectable levels
of anti-a-gal IgM Abs, i.e., 0.87 mg/ml (95% CI: 0.66–1.1 mg/ml),
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Figure 4. Protective Effect of a-Gal Immuni-
zation
(A) Anti-a-gal Abs in the serum of control () versus
rRBCM (+) or a-gal-BSA (+) immunized a1,3Gt/
mice (2–3 experiments; n = 12–29).
(B–D) Incidence of blood stage of infection (%) in
a1,3Gt/mice treated as in (A) and exposed to (B)
PbAEEF1a-GFP-infected A. stephensi mosquitoes
(seven experiments; n = 27–44), (C) P. yoelii
17XNL-infected A. stephensi mosquitoes (five
experiments; n = 28–39), or (D) PbAEEF1a-GFP-in-
fected A. gambiae mosquitoes (four experiments;
n = 27–34).
(E) Incidence of blood stage of infection (%)
in nonimmunized (control) versus immunized
(rRBCM) a1,3Gt/ mice receiving PbAEEF1a-GFP
sporozoites (3–4 experiments; n = 17–28).
(F) Plasmodium 18 s rRNA/Arbp0 mRNA in skin
and liver of nonimmunized (control) versus immu-
nized (rRBCM) a1,3Gt/ mice exposed to
PbAEEF1a-GFP-infected A. stephensi mosquitoes
(3–5 experiments). Infected/total mice (gray nbrs).
(G) Same as (A) in control () versus immunized
(+; rRBCM emulsified in CFA+CpG) a1,3Gt/
mice (two experiments; n = 6–23).
(H) Incidence of blood stage of infection (%) in
a1,3Gt/mice treated as in (G) and infected as in
(B) (three experiments; n = 16–19). In (A), (F), and
(G), dots are individual mice and mean (red bars).
See also Figures S3 and S4.suggesting that these are natural Abs (Figure 3F). The production
of anti-a-gal IgM Abs in GF a1,3Gt/ mice being driven by
expression of these glycans in food components is possible,
but this has not been tested. GF a1,3Gt/mice did not produce
anti-a-gal IgG Abs (Figure S2C). Susceptibility to PbA transmis-
sion by infected A. mosquitoes was similar in SPF versus GF
a1,3Gt/ mice (Figures 3D and 3G). When GF a1,3Gt/ mice
were monocolonized by E. coli O86:B7, the levels of circulating
anti-a-gal IgM Abs increased to 96.62 mg/ml (95% CI: 59.32–
133.9 mg/ml) (Figure 3F), which is the range in which adult individ-
uals from amalaria endemic region (Figure 2A), without concom-
itant induction of anti-a-gal IgG Abs (Figure S2C). Monocoloniza-
tion by E. coli O86:B7, but not by E. coli K12, protected
a1,3Gt/ mice from PbA transmission by A. mosquitoes (Fig-
ure 3F). This suggests that gut colonization by a specific patho-
biont expressing a-gal recapitulates to a large extent the normal
etiology of the human anti-a-gal Ab response (Figure 2) and in-Cell 159, 1277–1289, Dduces protection against Plasmodium
infection, such as observed in a malaria
endemic region (Figure 2).
It should be noted that the percentage
of infected red blood cell (RBC), i.e., para-
sitemia, and incidence of mortality were
similar among those a1,3Gt/ mice that
were infected by PbA regardless of
colonization (Figures S2B and S2D). This
suggests that gut colonization by E. coli
O86:B7 protects against Plasmodiumtransmission, but not against disease once the erythrocytic
stage of infection is established.
Immunization against a-Gal Protects from Plasmodium
Transmission
Immunization of a1,3Gt/mice against a-gal, using rabbit RBC
membranes (rRBCM) expressing high levels of a-gal or synthetic
a-gal conjugated to BSA (a-gal-BSA) elicited the production of
circulating anti-a-gal IgM and IgG Abs (Figure 4A). Control
a1,3Gt+/+ mice failed to produce anti-a-gal Abs (Chiang et al.,
2000; Tearle et al., 1996; Yang et al., 1998) (Figure S3A). Circu-
lating anti-a-gal immunoglobulin A (IgA) and immunoglobulin E
(IgE) Abs were undetectable in control or immunized a1,3Gt/
and a1,3Gt+/+ mice (data not shown). The concentration of
anti-a-gal IgM Abs in the plasma of immunized a1,3Gt/ mice
was in the range of adult individuals from malaria endemic re-
gions (Figure 2A). Circulating anti-a-gal IgG Abs in immunizedecember 4, 2014 ª2014 The Authors 1281
a1,3Gt/mice, predominantly from IgG1, IgG2b, and IgG3 sub-
classes, were present at higher concentrations, as compared to
total IgG in adult individuals from malaria endemic regions. Little
or no circulating IgG2a (Figure 4A) or IgG2c (data not shown)
were detected in immunized a1,3Gt/ mice.
Immunization against a-gal protected a1,3Gt/ mice from
PbA (Figure 4B) and P. yoelli 17XNL (Figure 4C) transmission
by infected A. stephensimosquitoes, as well as from PbA trans-
mission by A. gambiae mosquitoes (Figure 4D) versus control
nonimmunized a1,3Gt/ mice. Control immunized a1,3Gt+/+
mice were neither protected from PbA (Figure S3B) nor
P. yoelli 17XNL (Figure S3C) transmission by A. stephensi
mosquitoes nor against PbA transmission by A. gambiae
mosquitoes (Figure S3D) versus naive a1,3Gt+/+ mice.
Immunized a1,3Gt/ mice were protected from artificial
transmission of PbA sporozoites via intradermal inoculation
versus control nonimmunized a1,3Gt/ mice (Figure 4E) or
control immunized or nonimmunized a1,3Gt+/+ mice (Fig-
ure S3E). Protection was no longer observed when sporozoites
were inoculated intravenously (Figures 4E and S3E). This
suggests that the protective effect of a-gal immunization is
exerted in the dermis, presumably via an anti-a-gal Ab driven
mechanism that is no longer effective once sporozoites reach
the blood.
PbA transmission was associated with accumulation of Plas-
modium 18S rRNA at the site of inoculation, as quantified in
the ear pinna by qRT-PCR (Figure 4F). The relative amount of
Plasmodium 18S rRNA was similar in immunized versus control
nonimmunized a1,3Gt/mice (Figure 4F) or control immunized
or nonimmunized a1,3Gt+/+ mice (Figure S3F). Immunized
a1,3Gt/ mice did not accumulate Plasmodium 18S rRNA in
the liver, when compared to control nonimmunized a1,3Gt/
mice (Figure 4F) or control nonimmunized or immunized
a1,3Gt+/+ mice (Figure S3F). This suggests that a-gal immuniza-
tion arrests the transit of inoculated sporozoites from the skin
into the liver, without interfering with sporozoite inoculation by
A. mosquitoes.
TLR9 Agonist Adjuvant Enhances the Protective Effect
of a-Gal Immunization
Immunization of a1,3Gt/mice with rRBCM emulsified in com-
plete Freund’s adjuvant (CFA), supplemented with toll-like re-
ceptor 9 agonist CpG, enhanced anti-a-gal IgG2b and IgG3 Ab
response by 2- to 3-fold (Figure 4G) versus immunization without
adjuvant (Figure 4A). This was associated with 88% reduction
in the relative risk of transmission of PbA infection by A.
mosquitoes (95% CI: 0.032–0.452) versus 61% reduction upon
immunization without adjuvant (95% CI: 0.209–0.726) (Figures
4B and 4H). This protective effect was not observed in control
a1,3Gt+/+ mice (Figures S3G and S3H).
Parasitemias were similar in immunized a1,3Gt/ mice not
protected from PbA infection versus control nonimmunized
a1,3Gt/ mice as well as control nonimmunized or immunized
a1,3Gt+/+ mice (data not shown). Moreover, when infected, all
mice succumbed to experimental cerebral malaria. This sug-
gests that while protective against malaria transmission, a-gal
immunization is not protective against the development of se-
vere disease if Plasmodium manages to establish infection. In1282 Cell 159, 1277–1289, December 4, 2014 ª2014 The Authorskeeping with this notion, when inoculated with PbA-infected
RBC, immunized a1,3Gt/mice developed similar levels of par-
asitemia and disease severity, as compared to control nonimmu-
nized a1,3Gt/ mice as well as to control nonimmunized or
immunized a1,3Gt+/+ mice (Figure S4A).
We tested further whether the protective effect conferred by
a-gal immunization is associated with sterile protection, i.e.,
inability of Plasmodium to establish blood stage of infection.
Passive transfer of RBCs harvested from protected immunized
a1,3Gt/mice at day 8–9 post-PbA transmission by A.mosqui-
toes failed to transmit disease to naive a1,3Gt/ mice (Fig-
ure S4B). In contrast, passive transfer of RBC harvested from
nonprotected immunized a1,3Gt/ mice, readily transmitted
disease to naive a1,3Gt/mice (Figure S4B). This demonstrates
that the protective effect of immunization against a-gal is asso-
ciated with sterile protection against malaria.
Anti-a-Gal IgM and IgG Abs Produced in Response to
a-Gal Immunization Confer Protection against Malaria
Transmission
We asked whether the protective effect of a-gal immunization
is mediated by anti-a-gal IgM and/or IgG Abs. Immunized
a1,3Gt/JHT
/ mice failed to produce anti-a-gal IgM or IgG
Abs versus naive a1,3Gt/JHT
/ mice or immunized
a1,3Gt/ mice (Figure 5A). Moreover, immunized a1,3Gt/
JHT
/ mice were not protected against PbA transmission by
A. mosquitoes versus control nonimmunized a1,3Gt/JHT
/
mice (Figure 5B). This shows that the protective effect
of a-gal immunization is mediated via a B cell-dependent
mechanism.
Immunization of a1,3Gt/Aid/ mice failed to induce the
production of anti-a-gal IgG, but not IgM Abs, versus naive
a1,3Gt/Aid/ or immunized a1,3Gt/ mice (Figure 5A).
Immunized a1,3Gt/Aid/ mice were nevertheless pro-
tected against PbA transmission by A. mosquitoes versus non-
immunized a1,3Gt/Aid/ mice (Figure 5B). This confirms
that anti-a-gal IgM Abs can confer protection against malaria
transmission (Figure 2B) and that the protective effect of a-gal-
specific IgM Abs does not require somatic hypermutation.
Immunization of a1,3Gt/mS/ mice failed to induce anti-
a-gal IgM Abs, without interfering with anti-a-gal IgG Ab
response versus naive a1,3Gt/mS/ mice or immunized
a1,3Gt/ mice (Figure 5A). Immunized a1,3Gt/mS-/- mice
were nevertheless protected from PbA transmission by A.
mosquitoes versus control naive a1,3Gt/mS/ mice (Fig-
ure 5B). Immunized a1,3Gt/ mice did not produce circulating
anti-a-gal IgA or IgE Abs (data not shown) and a putative protec-
tive effect for these Ig isotypes was excluded. This demonstrates
that anti-a-gal IgG Abs produced in response to immunization
confer protection against malaria transmission.
Immunization of a1,3Gt/Tcrb/ mice lacking mature ab
T cells (Mombaerts et al., 1992) compromised anti-a-gal IgM
and IgG response versus control immunized a1,3Gt/ mice
(Figure 5A). Immunized a1,3Gt/Tcrb/ mice were not pro-
tected from PbA transmission by A. mosquitoes versus control
naive a1,3Gt/Tcrb/ mice (Figure 5B). This shows that anti-
a-gal Abs produced in response to immunization are T cell-
dependent (Cretin et al., 2002) and so is their protective effect.
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Figure 5. Protective Effect of Anti-a-Gal Abs
(A) Relative absorbance of anti-a-gal Abs (Mean ±
SD) in serial serum dilutions from nonimmunized
(NI) or rRBCM-immunized (I) a1,3Gt/ mice (two
experiments; n = 10).
(B) Incidence of blood stage infection (%) in spe-
cific immune component-deleted a1,3Gt/ mice
immunized (I) or not (NI) as in (A) and exposed to
PbAEEF1a-GFP-infected mosquitoes (3–7 experi-
ments; n = 13–41).
(C) Incidence of blood stage of infection (%) in
a1,3Gt/ mice after passive transfer of anti-a-gal
Abs versus controls (no passive transfer; ctr.)
exposed to PbAEEF1a-GFP-infected mosquitoes
(4–7 experiments; n = 19–32).
(D) C3 deposition in PbAHsp70-GFP sporozoites not
exposed (ctr.) or exposed to anti-a-gal Abs plus
mouse complement (C). Representative of three
independent experiments.
(E) Incidence of blood stage of infection (%) in
a1,3Gt/C3/mice after passive transfer of anti-
a-gal IgM (m), IgG2b (g2b), or IgG3 (g3) Abs versus
controls (ctr.; no passive transfer) not receiving
Abs, exposed to PbAEEF1a-GFP-infected mosqui-
toes (four experiments; n = 21–37).
(F) Same as (E) in PMN-depleted a1,3Gt/ mice
(four experiments; n = 15–25).
See also Figures S5 and S6.Naive and immunized a1,3Gt/JHT
/ (Figure S5A),
a1,3Gt/Aid/, (Figure S5B) and a1,3Gt/mS/ (Figure S5C)
mice, not protected from PbA transmission, developed similar
levels of parasitemia and succumbed to experimental cerebral
malaria. This was not the case for a1,3Gt/Tcrb/ mice (Fig-
ure S5D), consistent with the involvement of T cells in the path-
ogenesis of experimental cerebral malaria (Belnoue et al., 2002).
Passive transfer of anti-a-gal IgM to naive a1,3Gt/ mice
conferred protection against PbA transmission byA.mosquitoes
(Figure 5C). This was also the case for passive transfer of anti-
a-gal Abs from specific IgG subclasses, namely, IgG2b and
IgG3 (Figure 5C), but not IgG1 or IgG2a (Figure 5C). Relative
binding to a-gal was similar for all mAbs tested, as assessed
by ELISA using a-gal-BSA as a solid-phase antigen (Figure S6A)
or by immunofluorescence using PbA sporozoites (Figure S6B).
Specificity of anti-a-gal binding to Plasmodium sporozoites was
assessed by enzymatic removal of a-gal, confirming that these
mAbs recognize specifically and only the a-gal glycan on the sur-Cell 159, 1277–1289, Dface of Plasmodium sporozoites (Fig-
ure S6C). IgG2a, IgG2b, and IgG3 mAbs
are class-switched mutants derived from
the original anti-a-gal IgG1 clone and as
such have similar affinities for a-gal
(Ding et al., 2008). These data reveal that
while IgM anti-a-gal Abs are sufficient
per se to confer protection against ma-
laria transmission, this protective effect
can be enhanced when specific sub-
classes anti-a-gal IgG Abs are present at
sufficient high levels.Once bound to the surface of Plasmodium sporozoites, anti-
a-gal IgM, IgG2b, and IgG3 mAbs activated the classical
pathway of complement, as assessed by C3 deposition (Fig-
ure 5D). Anti-a-gal IgG1 or IgG2a mAbs failed to activate com-
plement (data not shown), and complement activation was
also not observed in the absence of anti-a-gal Abs (Figures 5D
and S7), showing that the alternative and lectin pathways of
complement are not activated by Plasmodium sporozoites.
We then asked whether the protective effect exerted by anti-
a-gal Abs is mediated via a mechanism involving the activation
of the complement cascade (Figure 5D) (Ding et al., 2008; Miya-
take et al., 1998). Passive transfer of anti-a-gal IgM Abs or anti-
a-gal IgG2b mAb to a1,3Gt/C3/ mice, which lack C3 and
cannot activate the complement cascade, failed to confer protec-
tion against PbA transmission versus control a1,3G/C3/
mice (Figure 5E). Passive transfer of anti-a-gal IgG3 mAb
to a1,3Gt/C3/ mice conferred residual but significant
protection versus control a1,3G/C3/ mice (Figure 5E). Thisecember 4, 2014 ª2014 The Authors 1283
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Figure 6. Protective Effect of Anti-a-Gal Abs
against Hepatocyte Infection
(A) Mean percentage (%) of viable GFP+
PbAHsp70-GFP sporozoites ± STD (3–4 experiments)
after exposure in vitro to anti-a-gal or control anti-
DNPmAbs in the presence of mouse complement.
(B and C) Mean percentage (%) of HepG2 cells (B)
wounded (Dextran-Red+) or (C) invaded (GFP+) by
PbAHsp70-GFP sporozoites treated as in (A) ± SD (six
experiments).suggests that the protective effect exerted by anti-a-gal IgM and
IgG2b Abs acts via a mechanism that is strictly complement
dependent, whereas the protective effect of anti-a-gal IgG3 Abs
is partially but probably not strictly dependent on complement
activation. Infection incidence was similar in control a1,3Gt/
C3/ versus a1,3Gt/C3+/+ mice (Figures 5C and 5E).
Complement activation generates C3a and C5a chemoattrac-
tants that promote IgG-dependent polymorphonuclear (PMN)
cell cytotoxicity (Ding et al., 2008; Nimmerjahn and Ravetch,
2008; Yin et al., 2004). Therefore, we asked whether the protec-
tive effect of anti-a-gal Abs involves PMN cells. Passive transfer
of anti-a-gal IgG2b Abs to a1,3Gt/ mice, depleted from PMN
cells by the administration of anti-Ly-6G (Gr-1) (Porcherie
et al., 2011), failed to confer protection against PbA transmission
by A. mosquitoes, whereas passive transfer of anti-a-gal IgM or
IgG3 Abs conferred protection (Figure 5F). This suggests that the
protective effect exerted by anti-a-gal IgM and IgG2b Abs acts
via a mechanism strictly dependent on PMN cells, whereas the
protective effect of anti-a-gal IgG3 Abs is partially but probably
not strictly dependent on PMN cells. Depletion of PMN cells
per se did not interfere with Plasmodium infection (Figure 5F)1284 Cell 159, 1277–1289, December 4, 2014 ª2014 The Authorswhile preventing the onset of cerebral ma-
laria (data not shown), consistent with
previous findings (Chen et al., 2000).
Anti-a-Gal Abs Are Cytotoxic to
Plasmodium Sporozoites
Complement activation by anti-a-gal IgM,
IgG2b, or IgG3mAb was cytotoxic to PbA
sporozoites in vitro, as assessed by
sporozoite GFP expression (Figure 6A).
Anti-a-gal IgG1 and IgG2a mAbs, which
did not activate complement when bound
to Plasmodium sporozoites (data not
shown), were not cytotoxic (Figure 6A).
The cytotoxic effect of anti-a-gal IgM,
IgG2b, and IgG3 was similar when using
mouse (Figure 6A) or rabbit (Figure S7A)
complement but was strictly dependent
on the presence of complement (Fig-
ure S7B). A similar cytotoxic effect was
observed when quantifying viable ‘‘cres-
cent-shaped’’ sporozoites (Figure S7C),
an independent readout for sporozoite
viability (Hegge et al., 2010). Isotype-
matched control anti-dinitrophenyl (DNP)Abs were not cytotoxic to PbA sporozoites in vitro (Figures 6A
and S7A–S7C).
Anti-a-Gal Abs Inhibit Hepatocyte Invasion by
Plasmodium Sporozoites
We asked whether anti-a-gal Abs inhibit hepatocyte transmigra-
tion (wounding) and/or hepatocyte invasion by Plasmodium spo-
rozoites (Mota et al., 2001). Complement activation by anti-a-gal
IgM, IgG2b, and IgG3 Abs inhibited hepatocyte transmigration
(Figure 6B) and invasion (Figure 6C), as assessed in vitro for
PbA sporozoites. This inhibitory effect was not observed when
using anti-a-gal IgG1 or IgG2a Abs or isotype/subclass-matched
control anti-DNP Abs (Figures 6B and 6C).
We then assessed whether anti-a-gal Abs inhibit the develop-
ment of exoerythrocytic forms (EEF) of Plasmodium. Comple-
ment activation by anti-a-gal IgM, IgG2b, and IgG3 Abs reduced
the number of EEF (Figure 7A), as well as the average EEF size
(Figures 7B and 7C) formed in vitro by PbA sporozoites. Anti-
a-gal IgG1 Abs did not show this inhibitory effect, while anti-
a-gal IgG2a Abs did not reduce the number of EEF (Figure 7A)
but had a residual inhibitory effect on EEF size (Figures 7B and
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Figure 7. Protective Effect of Anti-a-Gal
Abs against Plasmodium Maturation in
Hepatocytes
(A) Number of EEF per field (dots; 20–23 fields).
(B) Area of individual EEF (dots) (n = 111–256 EEFs
counted in 20–23 fields).
(C) Total area of EEF (dots) per field (20–23 fields).
HepG2 cells were incubated with PbAHsp70-GFP
sporozoites, previously exposed to anti-a-gal or
control anti-DNP mAbs in the presence of com-
plement (A–C).
See also Figure S7.7C). Isotype/subclass-matched control anti-DNP Abs did not
modulate EEF numbers (Figure 7A) or average size (Figures 7B
and 7C).
DISCUSSION
When inoculated in humans through the bite of an A. mosquito,
Plasmodium sporozoites are confronted with relatively high
levels of cytotoxic anti-a-gal IgM Abs (Figure 2A). That these
Abs are protective against malaria transmission is supported
by three independent lines of evidence. First, individuals from a
malaria endemic region that show evidence of decreased
P. falciparum infection risk have higher levels of circulating
a-gal-specific IgM Abs, as compared to individuals who are sus-
ceptible to P. falciparum infection (Figure 2B). Second, when
present at levels similar to those observed in individuals from a
malaria endemic region—in a1,3Gt/mice colonized by human
gut pathobiont E. coli O86:B7 expressing a-gal (Figure 3) or in
immunized a1,3Gt/ mice (Figures 4A and 4B)—anti-a-gal
IgM Abs confer protection against malaria transmission. Third,
passive transfer of anti-a-gal IgM Abs is sufficient per se to pro-
tect a1,3Gt/ mice from malaria transmission (Figure 5C).Cell 159, 1277–1289, DThe protective effect exerted by anti-
a-gal IgM Abs should be relevant to un-
derstand why malaria incidence is higher
in children versus adults from malaria
endemic regions (Modiano et al., 1996).
Relative absence of these antibodies
in children under the age of 2–3 years
should favor malaria transmission, as
compared to adults that have higher
levels of circulating anti-a-gal IgM Abs
(Figure 2A). This relative absence of anti-
a-gal IgM in children may be explained
by the (1) kinetics of establishment of an
adult-like gut microbiota (Ringel-Kulka
et al., 2013), (2) requirement of environ-
mental and dietary exposure in the estab-
lishment of an adult-like gut microbiota,
and/or (3) the kinetics of the establish-
ment of adult-like B cell repertoire,
including anti-a-gal B cells.
The protective effect exerted by anti-
a-gal IgM Abs might also contribute toexplain why only a small fraction of Plasmodium sporozoites
inoculated by mosquitoes manage to progress toward the
establishment of infection in humans. This is true even when
Plasmodium sporozoites are inoculated under controlled exper-
imental conditions in adults (Rickman et al., 1990; Sauerwein
et al., 2011; Verhage et al., 2005). Presumably, when present
at sufficient high levels in adults, circulating anti-a-gal IgM Abs
prevent the large majority of Plasmodium sporozoites from es-
tablishing a successful infection. However, infection is estab-
lished if as few as a couple of Plasmodium sporozoites manage
to escape this natural mechanism of protection.
Whether a-gal detected at the surface of Plasmodium sporo-
zoites (Figure 1) is produced by Plasmodium and/or by the mos-
quito is not clear. The salivary glands of noninfected mosquitoes
express low levels of a-gal, as detected bywestern blot (Figure 1)
and immunostaining (data not shown). Plasmodium sporozoites
aremasked bymosquito laminin (Warburg et al., 2007), an evolu-
tionary conserved glycoprotein that in other species contains
a-gal (Takahashi et al., 2014). It is possible therefore that anti-
a-gal Abs recognize laminin or another mosquito-derived protein
expressing a-gal, masking Plasmodium sporozoites (Warburg
et al., 2007).ecember 4, 2014 ª2014 The Authors 1285
It is now well established that specific components of the gut
microbiota can modulate immunity and resistance to infection
(Belkaid and Hand, 2014; Honda and Littman, 2012). In support
of this notion, resistance to viral and bacterial (Fagundes et al.,
2012) infections is impaired in GF mice (Dolowy and Muldoon,
1964) or mice subjected to antibiotic-driven dysbiosis (Ichinohe
et al., 2011). We reasoned that xeno-glycans expressed by spe-
cific components of the gut microbiota might trigger a protective
immune response against pathogens expressing the same xeno-
glycans.Weshow that this is thecase fora-gal, a xeno-glycan ex-
pressed by the human gut pathobiont E. coli O86:B7, as well by
Plasmodium spp. (Figures 1, 3A, and 3B). When colonized by
E. coli O86:B7, a1,3Gt/ mice produce an anti-a-gal IgM Ab
response (Figures 3C and 3F) that confer protection againstPlas-
modium infection (Figures 3D, 3E, 3G, and 5C) via a lytic mecha-
nism mediated by complement activation (Figures 5E and 6A). It
is worth noticing that in a similar manner to other microbiota-
driven resistance mechanisms, the protective effect exerted by
E. coli O86:B7 acts at the level of a tissue barrier, i.e., the skin,
to prevent Plasmodium transmission (Figures 4E and 4F).
Levels of circulating anti-a-gal IgG Abs in individuals from a
malaria endemic region (Figure 2C), as well as in a1,3Gt/
mice colonized with E. coli O86:B7 (Figures S2A and S2C), are
30-fold and 40 to 70-fold, respectively, lower than levels of
IgM anti-a-gal Abs. This may explain why basal levels anti-
a-gal IgG Abs in individuals from a malaria endemic region are
not associated with decreased risk of P. falciparum infection
(Figure 2D). This also suggests that P. falciparum infection fails
to induce class switch of the anti-a-gal Ig Ab response in those
individuals. It is possible therefore that P. falciparum represses
Ig class-switch recombination, explaining the residual levels of
circulating anti-a-gal IgG Abs (Figure 2C).
While anti-a-gal Abs can provide sterile protection against
malaria in mice (Figures 5B, 5C, and S4B), this is not commonly
observed in malaria endemic regions in which adult individuals
have circulating anti-a-gal IgM Abs, possibly because the levels
of these Abs are below a threshold level required to provide ster-
ile protection (Figure 2). However, we show that this natural
mechanism of protection can be enhanced via immunization us-
ing adjuvants that favor the production of T cell-dependent com-
plement fixing anti-a-gal IgG Abs (Figures 4G and 4H). Moreover,
when coupled to Plasmodium antigens, this approach should
enhance the immunogenicity of such antigens (Benatuil et al.,
2005) and boost the protective efficacy of candidate malaria
vaccines based on such antigens (Olotu et al., 2013). This
approach should be useful in preventing not only individual infec-
tions but also disease transmission given the protective effect of
anti-a-gal Abs.
It is possible that the protective effect of ‘‘attenuated’’ sporo-
zoite vaccine trials against malaria (Seder et al., 2013) is driven to
some extent by an anti-a-gal Ab response, given the expression
of a-gal by Plasmodium falciparum sporozoites (Figure 1).
Whether a correlation can be established between the effective-
ness of such candidate vaccines and a putative anti-a-gal IgGAb
response has not been established butmay be useful to consider
as a retrospective analyzes.
As a final note, we predict that in a similar manner to anti-a-gal
Abs other anti-glycan Abs may confer protection against malaria1286 Cell 159, 1277–1289, December 4, 2014 ª2014 The Authorsas well as other vector-borne protozoan parasites (Huflejt et al.,
2009; Lacroix-Desmazes et al., 1995; Nagele et al., 2013). More-
over, anti-a-gal Abs may also target other vector-borne proto-
zoan parasites expressing a-gal, such as Leishmania spp. and
Trypanosoma spp., the causative agents of Leishmaniasis and
Trypanosomiasis, respectively (Avila et al., 1989). As such,
vaccination approaches similar to the one proposed here for ma-
laria may be considered against these diseases as well.
EXPERIMENTAL PROCEDURES
Cohort Study
For detailed analysis, see the Extended Experimental Procedures.
Immunization against a-Gal
Eight- to ten-week-old mice received 3 3 108 rabbit rRBCM equivalents
(100 ml; PBS; intraperitoneal [i.p.]). Adjuvants are described in the Extended
Experimental Procedures. Mouse serum was collected 2 weeks after last
immunization, and circulating anti-a-gal Abs were quantified by ELISA. See
the Extended Experimental Procedures for details on anti-a-gal ELISA.
Passive Transfer of Anti-a-Gal mAbs
a1,3Gt/mice received anti-a-gal IgG1, IgG2a, IgG2b, and IgG3 mAbs (Ding
et al., 2008; Yin et al., 2004) (150 mg; 100 ml per mouse) or polyclonal IgM
(150 mg; 300–400 ml per mouse) via a single intravenous (i.v.) injection 24 hr
prior to mosquito exposure.
Plasmodium Strains
Transgenic P. berghei ANKA (PbA) strains expressing GFP under the eef1a
promoter, i.e., PbAEEF1a-GFP (259cl1; MR4; MRA-865) (Franke-Fayard et al.,
2004), or under the hsp70 promoter (Ishino et al., 2006), i.e., PbAHsp70-GFP
(kindly provided by Robert Menard, Institut Pasteur), transgenic P. yoelii
17XNL strain expressing GFP under the PbA eef1a promoter (MR4; MRA-
817; kindly provided by Robert Menard, Institut Pasteur) (Weiss et al., 1989).
For sporozoite production, see the Extended Experimental Procedures.
Plasmodium Transmission
A. stephensi or gambiae mosquitoes were allowed to feed on anesthetized
mice (i.p.; 125 mg/kg ketamine; 12.5 mg/kg xylazine) placed on a warming
tray. Two mosquitoes were allowed to probe and feed independently (90–
100 s) on restricted to the edge of the mouse ear (10–12/3–4 mm) and
dissected thereafter for confirmation of sporozoites in salivary glands. If nega-
tive, infection was repeated.
Sporozoites Inoculation
PbAEEF1a-GFP sporozoites were inoculated (i.d.) in the ear pinna (750 sporozo-
ites in 20–30 ml; 1%BSA in PBS) or i.v. in the retro-orbital vein (150 sporozoites
in 50 ml; 1% BSA in PBS) using a microsyringe (Nanofil 100 ml; 33G beveled
needle; World Precision Instruments).
Detection of a-Gal in Plasmodium Sporozoites
Sporozoites were stained with Alexa Fluor 647-conjugated BSI-IB4 or Alexa
Fluor 647-conjugated anti-a-gal mAbs and detected by confocal microscope
or flow cytometer. For detection of a-gal in PbAHsp70-GFP by western blotting,
see the Extended Experimental Procedures. Green coffee bean a-galactosi-
dase (50–200 ml; 5 U/ml; 60–90 min; 25C; Sigma Chemical) was used to hy-
drolyze terminal a-galactosyl moieties from glycolipids and glycoproteins
(Luo et al., 1999).
Statistical Analysis
All tests (except human cohort studies) were performed using the GraphPad
Prism (v. 6.0) (GraphPad Software). Human analyses were performed in R
(v. 3.0.2). Detailed analyses are described in the Extended Experimental
Procedures.
Mice
Experiments in mice were performed in accordance with protocols approved
by the Ethics Committee of the Instituto Gulbenkian de Cieˆncia and the Portu-
guese National Entity (DGAV-Direc¸a˜o Geral de Alimentac¸a˜o e Veterina´ria).
Experiments in mice were performed in accordance with the Portuguese
(Decreto-Lei no. 113/2013) and European (directive 2010/63/EU) legislation
related to housing, husbandry, and animal welfare. C57BL/6 JHT
/ (Gu
et al., 1993), Tcrb/ (Mombaerts et al., 1992), Aid/ (Muramatsu et al.,
2000), mS/ (Ehrenstein et al., 1998), and C3/ (Circolo et al., 1999) mice
were crossed with C57BL/6 a1,3Gt/ mice (Shinkel et al., 1997; Tearle
et al., 1996). For the details on genotyping, see the Extended Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
seven figures and can be found with this article online at http://dx.doi.org/
10.1016/j.cell.2014.10.053.
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